Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 120 entries
Sorted by: Best Match Show Resources per page
Institutional review of glial tumors treated with chemotherapy: the first description of PCV-related pseudoprogression.

Neuro-oncology practice

Sharma AM, Willcock M, Bucher O, Amaratunga T, Khan MN, Loewen SK, Quon H, Essig M, Pitz M.
PMID: 31385994
Neurooncol Pract. 2019 Jan;6(1):22-29. doi: 10.1093/nop/npy012. Epub 2018 May 21.

BACKGROUND: Pseudoprogression refers to areas of enhancement on MRI postadjuvant chemoradiation that arise as a result of treatment-related effects. Pseudoprogression has been well described with temozolomide-based chemoradiation but has not been studied in the setting of procarbazine, lomustine, and...

Cite
Sharma AM, Willcock M, Bucher O, et al. Institutional review of glial tumors treated with chemotherapy: the first description of PCV-related pseudoprogression. Neurooncol Pract. 2018;6(1):22-29doi: 10.1093/nop/npy012.
Sharma, A. M., Willcock, M., Bucher, O., Amaratunga, T., Khan, M. N., Loewen, S. K., Quon, H., Essig, M., & Pitz, M. (2019). Institutional review of glial tumors treated with chemotherapy: the first description of PCV-related pseudoprogression. Neuro-oncology practice, 6(1), 22-29. https://doi.org/10.1093/nop/npy012
Sharma, Ankur M, et al. "Institutional review of glial tumors treated with chemotherapy: the first description of PCV-related pseudoprogression." Neuro-oncology practice vol. 6,1 (2019): 22-29. doi: https://doi.org/10.1093/nop/npy012
Sharma AM, Willcock M, Bucher O, Amaratunga T, Khan MN, Loewen SK, Quon H, Essig M, Pitz M. Institutional review of glial tumors treated with chemotherapy: the first description of PCV-related pseudoprogression. Neurooncol Pract. 2019 Jan;6(1):22-29. doi: 10.1093/nop/npy012. Epub 2018 May 21. PMID: 31385994; PMCID: PMC6656297.
Copy Download .nbib Format: NLM
ESHAP chemotherapy is efficient in refractory/relapsed primary central nervous system lymphoma: report of four cases.

OncoTargets and therapy

Ungur R, Tempescul A, Berthou C, Bagacean C, Radeanu D, Muresan A, Zdrenghea M.
PMID: 26491351
Onco Targets Ther. 2015 Oct 01;8:2771-3. doi: 10.2147/OTT.S89358. eCollection 2015.

Primary central nervous system non-Hodgkin's lymphoma is a rare presentation, almost always of diffuse large B-cell type. Although there is no consensus regarding therapy for this condition, induction regimens are based on high-dose methotrexate and consolidation whole-brain radiotherapy, or,...

Cite
Ungur R, Tempescul A, Berthou C, et al. ESHAP chemotherapy is efficient in refractory/relapsed primary central nervous system lymphoma: report of four cases. Onco Targets Ther. 2015;8:2771-3doi: 10.2147/OTT.S89358.
Ungur, R., Tempescul, A., Berthou, C., Bagacean, C., Radeanu, D., Muresan, A., & Zdrenghea, M. (2015). ESHAP chemotherapy is efficient in refractory/relapsed primary central nervous system lymphoma: report of four cases. OncoTargets and therapy, 82771-3. https://doi.org/10.2147/OTT.S89358
Ungur, Rodica, et al. "ESHAP chemotherapy is efficient in refractory/relapsed primary central nervous system lymphoma: report of four cases." OncoTargets and therapy vol. 8 (2015): 2771-3. doi: https://doi.org/10.2147/OTT.S89358
Ungur R, Tempescul A, Berthou C, Bagacean C, Radeanu D, Muresan A, Zdrenghea M. ESHAP chemotherapy is efficient in refractory/relapsed primary central nervous system lymphoma: report of four cases. Onco Targets Ther. 2015 Oct 01;8:2771-3. doi: 10.2147/OTT.S89358. eCollection 2015. PMID: 26491351; PMCID: PMC4599053.
Copy Download .nbib Format: NLM
Alkylation and Carbamylation Effects of Lomustine and Its Major Metabolites and MGMT Expression in Canine Cells.

Veterinary sciences

Chakkath T, Lavergne S, Fan TM, Bunick D, Dirikolu L.
PMID: 29061931
Vet Sci. 2015 Apr 24;2(2):52-68. doi: 10.3390/vetsci2020052.

DNA Alkylation is thought to be the reason for the efficacy of lomustine while carbamylation has been implicated as the cause for the side effects seen with lomustine treatment such as hepatotoxicity. In the alkylation study we show that...

Cite
Chakkath T, Lavergne S, Fan TM, et al. Alkylation and Carbamylation Effects of Lomustine and Its Major Metabolites and MGMT Expression in Canine Cells. Vet Sci. 2015;2(2):52-68doi: 10.3390/vetsci2020052.
Chakkath, T., Lavergne, S., Fan, T. M., Bunick, D., & Dirikolu, L. (2015). Alkylation and Carbamylation Effects of Lomustine and Its Major Metabolites and MGMT Expression in Canine Cells. Veterinary sciences, 2(2), 52-68. https://doi.org/10.3390/vetsci2020052
Chakkath, Thushara, et al. "Alkylation and Carbamylation Effects of Lomustine and Its Major Metabolites and MGMT Expression in Canine Cells." Veterinary sciences vol. 2,2 (2015): 52-68. doi: https://doi.org/10.3390/vetsci2020052
Chakkath T, Lavergne S, Fan TM, Bunick D, Dirikolu L. Alkylation and Carbamylation Effects of Lomustine and Its Major Metabolites and MGMT Expression in Canine Cells. Vet Sci. 2015 Apr 24;2(2):52-68. doi: 10.3390/vetsci2020052. PMID: 29061931; PMCID: PMC5644621.
Copy Download .nbib Format: NLM
Procarbazine, CCNU and vincristine (PCV) versus temozolomide chemotherapy for patients with low-grade glioma: a systematic review.

Oncotarget

Hafazalla K, Sahgal A, Jaja B, Perry JR, Das S.
PMID: 30263090
Oncotarget. 2018 Sep 14;9(72):33623-33633. doi: 10.18632/oncotarget.25890. eCollection 2018 Sep 14.

Low-grade gliomas (LGG) encompass a heterogeneous group of tumors that are clinically, histologically and molecularly diverse. Treatment decisions for patients with LGG are directed toward improving upon the natural history while limiting treatment-associated toxiceffects. Recent evidence has documented a...

Cite
Hafazalla K, Sahgal A, Jaja B, et al. Procarbazine, CCNU and vincristine (PCV) versus temozolomide chemotherapy for patients with low-grade glioma: a systematic review. Oncotarget. 2018;9(72):33623-33633doi: 10.18632/oncotarget.25890.
Hafazalla, K., Sahgal, A., Jaja, B., Perry, J. R., & Das, S. (2018). Procarbazine, CCNU and vincristine (PCV) versus temozolomide chemotherapy for patients with low-grade glioma: a systematic review. Oncotarget, 9(72), 33623-33633. https://doi.org/10.18632/oncotarget.25890
Hafazalla, Karim, et al. "Procarbazine, CCNU and vincristine (PCV) versus temozolomide chemotherapy for patients with low-grade glioma: a systematic review." Oncotarget vol. 9,72 (2018): 33623-33633. doi: https://doi.org/10.18632/oncotarget.25890
Hafazalla K, Sahgal A, Jaja B, Perry JR, Das S. Procarbazine, CCNU and vincristine (PCV) versus temozolomide chemotherapy for patients with low-grade glioma: a systematic review. Oncotarget. 2018 Sep 14;9(72):33623-33633. doi: 10.18632/oncotarget.25890. eCollection 2018 Sep 14. PMID: 30263090; PMCID: PMC6154749.
Copy Download .nbib Format: NLM
Evaluation of O6-methylguanine-DNA methyltransferase enzyme expression effect on survival of patients with Grade 4 brain astrocytoma.

Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences

Hemati S, Sayadi A, Mahzooni P, Sirous M.
PMID: 25097625
J Res Med Sci. 2014 May;19(5):426-32.

BACKGROUND: High-grade astrocytoma (Grade 4) or glioblastoma multiforme (GBM) are deadly brain tumors. New therapies attempt to increase lifetime and quality of life in patients with malignant astrocytoma. O6-methylguanine-DNA methyltransferase (MGMT) enzyme expression may be effective in prognosis and...

Cite
Hemati S, Sayadi A, Mahzooni P, et al. Evaluation of O6-methylguanine-DNA methyltransferase enzyme expression effect on survival of patients with Grade 4 brain astrocytoma. J Res Med Sci. 2014;19(5):426-32
Hemati, S., Sayadi, A., Mahzooni, P., & Sirous, M. (2014). Evaluation of O6-methylguanine-DNA methyltransferase enzyme expression effect on survival of patients with Grade 4 brain astrocytoma. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences, 19(5), 426-32.
Hemati, Simin, et al. "Evaluation of O6-methylguanine-DNA methyltransferase enzyme expression effect on survival of patients with Grade 4 brain astrocytoma." Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences vol. 19,5 (2014): 426-32.
Hemati S, Sayadi A, Mahzooni P, Sirous M. Evaluation of O6-methylguanine-DNA methyltransferase enzyme expression effect on survival of patients with Grade 4 brain astrocytoma. J Res Med Sci. 2014 May;19(5):426-32. PMID: 25097625; PMCID: PMC4116574.
Copy Download .nbib Format: NLM
Guidelines for the treatment of adult intra-cranial grade II-III ependymal tumours.

Forum (Genoa, Italy)

Reni M.
PMID: 14732890
Forum (Genova). 2003;13(1):90-8.

Intra-cranial ependymal tumours are very rare in the adult population, so most of reported series are retrospective, include also paediatric patients and have limited statistical power due to the small number of cases. As a consequence, universally accepted prognostic...

Cite
Reni M. Guidelines for the treatment of adult intra-cranial grade II-III ependymal tumours. Forum (Genova). 2003;13(1):90-8
Reni, M. (2003). Guidelines for the treatment of adult intra-cranial grade II-III ependymal tumours. Forum (Genoa, Italy), 13(1), 90-8.
Reni, M. "Guidelines for the treatment of adult intra-cranial grade II-III ependymal tumours." Forum (Genoa, Italy) vol. 13,1 (2003): 90-8.
Reni M. Guidelines for the treatment of adult intra-cranial grade II-III ependymal tumours. Forum (Genova). 2003;13(1):90-8. PMID: 14732890.
Copy Download .nbib Format: NLM
The role of chemotherapy in anaplastic astrocytoma patients.

Journal of Korean Neurosurgical Society

Kim SK, Kim JW, Kim YH, Kim TM, Lee SH, Park CK.
PMID: 22737298
J Korean Neurosurg Soc. 2012 Apr;51(4):199-202. doi: 10.3340/jkns.2012.51.4.199. Epub 2012 Apr 30.

OBJECTIVE: This retrospective study was performed to evaluate the role of chemotherapy in the management of patients with anaplastic astrocytoma (AA).METHODS: We compared the survival outcome among the 3 different treatment protocol groups in a single institution. A total...

Cite
Kim SK, Kim JW, Kim YH, et al. The role of chemotherapy in anaplastic astrocytoma patients. J Korean Neurosurg Soc. 2012;51(4):199-202doi: 10.3340/jkns.2012.51.4.199.
Kim, S. K., Kim, J. W., Kim, Y. H., Kim, T. M., Lee, S. H., & Park, C. K. (2012). The role of chemotherapy in anaplastic astrocytoma patients. Journal of Korean Neurosurgical Society, 51(4), 199-202. https://doi.org/10.3340/jkns.2012.51.4.199
Kim, Sung Kwon, et al. "The role of chemotherapy in anaplastic astrocytoma patients." Journal of Korean Neurosurgical Society vol. 51,4 (2012): 199-202. doi: https://doi.org/10.3340/jkns.2012.51.4.199
Kim SK, Kim JW, Kim YH, Kim TM, Lee SH, Park CK. The role of chemotherapy in anaplastic astrocytoma patients. J Korean Neurosurg Soc. 2012 Apr;51(4):199-202. doi: 10.3340/jkns.2012.51.4.199. Epub 2012 Apr 30. PMID: 22737298; PMCID: PMC3377875.
Copy Download .nbib Format: NLM
Efficacy and toxicity of BOPP and LOPP chemotherapy for the treatment of relapsed canine lymphoma.

Veterinary and comparative oncology

LeBlanc AK, Mauldin GE, Milner RJ, LaDue TA, Mauldin GN, Bartges JW.
PMID: 19754826
Vet Comp Oncol. 2006 Mar;4(1):21-32. doi: 10.1111/j.1476-5810.2006.00088.x.

Mechlorethamine (Mustargen), Oncovin) (vincristine), procarbazine and prednisone (MOPP) chemotherapy is useful for relapsed canine lymphoma. This study evaluates the efficacy of MOPP after substitution of CCNU (lomustine, LOPP protocol) or BCNU (carmustine, BOPP protocol) for mechlorethamine in 60 dogs...

Cite
LeBlanc AK, Mauldin GE, Milner RJ, et al. Efficacy and toxicity of BOPP and LOPP chemotherapy for the treatment of relapsed canine lymphoma. Vet Comp Oncol. 2006;4(1):21-32doi: 10.1111/j.1476-5810.2006.00088.x.
LeBlanc, A. K., Mauldin, G. E., Milner, R. J., LaDue, T. A., Mauldin, G. N., & Bartges, J. W. (2006). Efficacy and toxicity of BOPP and LOPP chemotherapy for the treatment of relapsed canine lymphoma. Veterinary and comparative oncology, 4(1), 21-32. https://doi.org/10.1111/j.1476-5810.2006.00088.x
LeBlanc, A K, et al. "Efficacy and toxicity of BOPP and LOPP chemotherapy for the treatment of relapsed canine lymphoma." Veterinary and comparative oncology vol. 4,1 (2006): 21-32. doi: https://doi.org/10.1111/j.1476-5810.2006.00088.x
LeBlanc AK, Mauldin GE, Milner RJ, LaDue TA, Mauldin GN, Bartges JW. Efficacy and toxicity of BOPP and LOPP chemotherapy for the treatment of relapsed canine lymphoma. Vet Comp Oncol. 2006 Mar;4(1):21-32. doi: 10.1111/j.1476-5810.2006.00088.x. PMID: 19754826.
Copy Download .nbib Format: NLM
Anaplastic oligodendroglioma.

Current treatment options in neurology

Blakeley J, Grossman S.
PMID: 18579016
Curr Treat Options Neurol. 2008 Jul;10(4):295-307. doi: 10.1007/s11940-008-0032-y.

Although uncommon, anaplastic oligodendrogliomas (AODs) are important to recognize, as they have unique molecular, histologic, and clinical features. Patients with new seizures or new focal neurologic deficits should be referred for brain MRI with contrast. If the MRI suggests...

Cite
Blakeley J, Grossman S. Anaplastic oligodendroglioma. Curr Treat Options Neurol. 2008;10(4):295-307doi: 10.1007/s11940-008-0032-y.
Blakeley, J., & Grossman, S. (2008). Anaplastic oligodendroglioma. Current treatment options in neurology, 10(4), 295-307. https://doi.org/10.1007/s11940-008-0032-y
Blakeley, Jaishri, and Grossman, Stuart. "Anaplastic oligodendroglioma." Current treatment options in neurology vol. 10,4 (2008): 295-307. doi: https://doi.org/10.1007/s11940-008-0032-y
Blakeley J, Grossman S. Anaplastic oligodendroglioma. Curr Treat Options Neurol. 2008 Jul;10(4):295-307. doi: 10.1007/s11940-008-0032-y. PMID: 18579016; PMCID: PMC3994534.
Copy Download .nbib Format: NLM
Efficacy of Procarbazine, Lomustine, and Vincristine Chemotherapy for Recurrent Primary Central Nervous System Lymphomas.

Brain tumor research and treatment

Kim YJ, Choe JH, Park JH, Hong YK.
PMID: 26605261
Brain Tumor Res Treat. 2015 Oct;3(2):75-80. doi: 10.14791/btrt.2015.3.2.75. Epub 2015 Oct 30.

BACKGROUND: Optimal treatment for recurrent primary central nervous system lymphomas (PCNSLs) has not been defined yet and there is no general consensus about the salvage chemotherapy after high-dose methotrexate (HD-MTX)-based chemotherapy. The purpose of the present study was to...

Cite
Kim YJ, Choe JH, Park JH, et al. Efficacy of Procarbazine, Lomustine, and Vincristine Chemotherapy for Recurrent Primary Central Nervous System Lymphomas. Brain Tumor Res Treat. 2015;3(2):75-80doi: 10.14791/btrt.2015.3.2.75.
Kim, Y. J., Choe, J. H., Park, J. H., & Hong, Y. K. (2015). Efficacy of Procarbazine, Lomustine, and Vincristine Chemotherapy for Recurrent Primary Central Nervous System Lymphomas. Brain tumor research and treatment, 3(2), 75-80. https://doi.org/10.14791/btrt.2015.3.2.75
Kim, Young-Joo, et al. "Efficacy of Procarbazine, Lomustine, and Vincristine Chemotherapy for Recurrent Primary Central Nervous System Lymphomas." Brain tumor research and treatment vol. 3,2 (2015): 75-80. doi: https://doi.org/10.14791/btrt.2015.3.2.75
Kim YJ, Choe JH, Park JH, Hong YK. Efficacy of Procarbazine, Lomustine, and Vincristine Chemotherapy for Recurrent Primary Central Nervous System Lymphomas. Brain Tumor Res Treat. 2015 Oct;3(2):75-80. doi: 10.14791/btrt.2015.3.2.75. Epub 2015 Oct 30. PMID: 26605261; PMCID: PMC4656899.
Copy Download .nbib Format: NLM
Procarbazine, Lomustine, and Vincristine (PCV) Regimen for Central Nervous System Tumors.

Hospital pharmacy

Solimando DA, Waddell JA.
PMID: 28321136
Hosp Pharm. 2017 Feb;52(2):98-104. doi: 10.1310/hpj5202-98.

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and...

Cite
Solimando DA, Waddell JA. Procarbazine, Lomustine, and Vincristine (PCV) Regimen for Central Nervous System Tumors. Hosp Pharm. 2017;52(2):98-104doi: 10.1310/hpj5202-98.
Solimando, D. A., & Waddell, J. A. (2017). Procarbazine, Lomustine, and Vincristine (PCV) Regimen for Central Nervous System Tumors. Hospital pharmacy, 52(2), 98-104. https://doi.org/10.1310/hpj5202-98
Solimando, Dominic A, and Waddell, J Aubrey. "Procarbazine, Lomustine, and Vincristine (PCV) Regimen for Central Nervous System Tumors." Hospital pharmacy vol. 52,2 (2017): 98-104. doi: https://doi.org/10.1310/hpj5202-98
Solimando DA, Waddell JA. Procarbazine, Lomustine, and Vincristine (PCV) Regimen for Central Nervous System Tumors. Hosp Pharm. 2017 Feb;52(2):98-104. doi: 10.1310/hpj5202-98. PMID: 28321136; PMCID: PMC5345921.
Copy Download .nbib Format: NLM
Brain perfusion and permeability in patients with advanced, refractory glioblastoma treated with lomustine and the transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate.

Oncology letters

Sepulveda-Sanchez J, Ramos A, Hilario A, DE Velasco G, Castellano D, Garcia DE LA Torre M, Rodon J, Lahn MF.
PMID: 26137087
Oncol Lett. 2015 Jun;9(6):2442-2448. doi: 10.3892/ol.2015.3106. Epub 2015 Apr 08.

Transforming growth factor-β (TGF-β) signaling is associated with tumor progression and vascularization in malignant glioma. In the present study, magnetic resonance imaging was used to evaluate changes in the size and vascularity of glioblastomas in 12 patients who were...

Cite
Sepulveda-Sanchez J, Ramos A, Hilario A, et al. Brain perfusion and permeability in patients with advanced, refractory glioblastoma treated with lomustine and the transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate. Oncol Lett. 2015;9(6):2442-2448doi: 10.3892/ol.2015.3106.
Sepulveda-Sanchez, J., Ramos, A., Hilario, A., DE Velasco, G., Castellano, D., Garcia DE LA Torre, M., Rodon, J., & Lahn, M. F. (2015). Brain perfusion and permeability in patients with advanced, refractory glioblastoma treated with lomustine and the transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate. Oncology letters, 9(6), 2442-2448. https://doi.org/10.3892/ol.2015.3106
Sepulveda-Sanchez, Juan, et al. "Brain perfusion and permeability in patients with advanced, refractory glioblastoma treated with lomustine and the transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate." Oncology letters vol. 9,6 (2015): 2442-2448. doi: https://doi.org/10.3892/ol.2015.3106
Sepulveda-Sanchez J, Ramos A, Hilario A, DE Velasco G, Castellano D, Garcia DE LA Torre M, Rodon J, Lahn MF. Brain perfusion and permeability in patients with advanced, refractory glioblastoma treated with lomustine and the transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate. Oncol Lett. 2015 Jun;9(6):2442-2448. doi: 10.3892/ol.2015.3106. Epub 2015 Apr 08. PMID: 26137087; PMCID: PMC4473383.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 120 entries